<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="NEW YORK, NY / ACCESSWIRE / September 16, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.” data-reactid=”11″>NEW YORK, NY / ACCESSWIRE / September 16, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Netflix, Inc. (NFLX)” data-reactid=”12″>Netflix, Inc. (NFLX)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Lawsuit on behalf of: investors who purchased April 17, 2019 – July 17, 2019
Lead Plaintiff Deadline : September 20, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/netflix-inc-loss-form?prid=3513&wire=1” data-reactid=”13″>Lawsuit on behalf of: investors who purchased April 17, 2019 – July 17, 2019
Lead Plaintiff Deadline : September 20, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/netflix-inc-loss-form?prid=3513&wire=1
According to the filed complaint, during the class period, Netflix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Mallinckrodt Public Limited Company (MNK)” data-reactid=”15″>Mallinckrodt Public Limited Company (MNK)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Lawsuit on behalf of: investors who purchased February 28, 2018 – July 16, 2019
Lead Plaintiff Deadline : September 24, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/mallinckrodt-public-limited-company-loss-form?prid=3513&wire=1” data-reactid=”16″>Lawsuit on behalf of: investors who purchased February 28, 2018 – July 16, 2019
Lead Plaintiff Deadline : September 24, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/mallinckrodt-public-limited-company-loss-form?prid=3513&wire=1
According to the filed complaint, during the class period, Mallinckrodt Public Limited Company made materially false and/or misleading statements and/or failed to disclose that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Abiomed, Inc. (ABMD)” data-reactid=”18″>Abiomed, Inc. (ABMD)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Lawsuit on behalf of: investors who purchased January 31, 2019 – July 31, 2019
Lead Plaintiff Deadline : October 7, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abiomed-inc-loss-form?prid=3513&wire=1” data-reactid=”19″>Lawsuit on behalf of: investors who purchased January 31, 2019 – July 31, 2019
Lead Plaintiff Deadline : October 7, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abiomed-inc-loss-form?prid=3513&wire=1
According to the filed complaint, during the class period, Abiomed, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Abiomed’s revenue growth was in decline; (ii) the Company did not have a sufficient plan in place to stem its declining revenue growth; (iii) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (iv) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.” data-reactid=”21″>You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com” data-reactid=”23″>CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="SOURCE: Levi & Korsinsky, LLP” data-reactid=”24″>SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/559805/CLASS-ACTION-UPDATE-for-NFLX-MNK-and-ABMD-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
Add Comment